Faculty

Narendra Kanuru

MD
Director of Electrophysiology
Wellstar Health System

Narendra Kanuru is the director of Electrophysiology at the Wellstar Health System based in metro-Atlanta, Georgia. Dr. Kanuru was raised in Sheffield, Alabama and attended college and medical school in the combined 6-year BS/MD program at the University of Miami. He trained at Emory and completed his EP fellowship in 2002. He then joined Wellstar to start the Electrophysiology program. The Wellstar Cardiology division currently has over 100cardiologists and 8 electrophysiologists.

2027 Sessions

Session 6

  • Moderator
    • Jared Bunch, MD
    • Narendra Kanuru, MD

What Do Blood Biomarkers Reveal About the Reality of PFA?

Speaker

Friday, February 26 4:05–4:15 PM
Faculty

Dhanunjaya Lakkireddy

MD, MBA
Medical Director
Kansas CIty Heart Rhythm Institute

Dr. Dhanunjaya R Lakkireddy, Executive Medical Director of the Kansas City Heart Rhythm Institute at HCA Midwest in Overland Park, Kansas. He is an adjunct Professor of Medicine at the University of Missouri-Columbia. Dr. Lakkireddy has published over three hundred peer reviewed papers and abstracts in various national and international meetings and journals. Dr. Lakkireddy's clinical practice is focused on Arrhythmia Management, Atrial fibrillation ablation, Supraventricular Tachycardia, Ventricular Arrhythmia Ablation, Stereotaxis Magnetic Navigation System, and Pacemaker/ implantable cardioverter defibrillator/cardiac resynchronization therapy/ leadless pacemakers/Lead Extraction. Dr. Lakkireddy's specialties include Cardiology, Alternative/Complementary Med, Arrhythmia Management, Cardiac Electrophysiology, and Cardiovascular Research.

He has done extensive research on oral anticoagulation and systemic thromboembolization. He published seminal papers on uninterrupted oral anticoagulation and cardiac arrhythmia procedures. He is internationally known for his expertise in the left atrial appendage closure devices. His work on the connection between myocarditis and premature ventricular contractions and non-ischemic cardiomyopathy has gained significant recognition in the scientific circles.

Are GLP-1s and SGLT2 Inhibitors Now Part of Guideline-Directed Therapy for AFib?

Speaker

Friday, February 26 4:15–4:25 PM
Faculty

Leslie Cho

Proposing New AFib Classification System

Speaker

Friday, February 26 4:25–4:35 PM
Faculty

Han Feng

PhD
Assistant Professor
Tulane University

Dr. Feng is a Research Assistant Professor at Tulane University School of Medicine and an independent cardiovascular data science investigator with expertise in biostatistics, machine learning, causal inference, and real-world evidence analysis. His research sits at the interface of clinical electrophysiology and quantitative methodology, with a central focus on transforming complex cardiovascular data into clinically actionable evidence to understand atrial fibrillation mechanisms, model disease progression, and personalize treatment strategies. Trained in biostatistics and machine learning, Dr. Feng integrates clinical insight with advanced analytic methods across large-scale electronic health records, Electrocardiograms, wearable sensors, cardiac imaging, ablation procedures, clinical trials, and genetic data. At Tulane, he has played leading scientific, quantitative, and operational roles in major cardiovascular research studies, including HEARTBEAT and CASTLE-HFpEF. He also leads a multidisciplinary cardiovascular data science team of postdoctoral fellows, machine learning engineers, biostatisticians, and medical students conducting studies using large-scale real-world and multimodal datasets. His work spans the full research workflow, from clinical question formulation to analysis and clinical interpretation. With more than 50 peer-reviewed journal articles and more than 100 peer-reviewed conference abstracts, Dr. Feng has established a research program that bridges cardiovascular science, advanced quantitative methodology, and translational decision support, with ongoing work focused on AF treatment optimization and dynamic cardiovascular risk prediction in multimodal data settings.

Seperating the Hope from the Hype of Zero Bleeding with Factor XIa Inhibitors

Speaker

Friday, February 26 4:35–4:45 PM
Faculty

Andrea Russo

MD
Professor of Medicine, Cooper Medical School of Rowan University; Academic Chief, Division of Cardiology; Director Electrophysiology & Arrhythmia Services
Cooper University Health Care

Dr. Russo is currently Professor of Medicine at Cooper Medical School of Rowan University, Academic Chief of the Division of Cardiology, Director of Electrophysiology and Arrhythmia Services, and Director of the Clinical Cardiac Electrophysiology Fellowship Program at Cooper University Health Care in Camden, New Jersey. She was Past President of the Heart Rhythm Society. She has authored multiple manuscripts on a variety of arrhythmia and device topics and has been co-chair or member of various writing groups, including guideline, consensus, and appropriate use documents. In addition, she is a current Associate Editor for Circulation and Associate Editor for Circulation: Arrhythmia and Electrophysiology and serves on the editorial board for several peer reviewed journals. She has also served on steering committees, events committees, and data safety monitoring committees for several clinical trials. Areas of special interest include sex differences in arrhythmias, implantable cardioverter defibrillators, atrial fibrillation therapy, and the role of digital health in arrhythmia management.

Discussion

Friday, February 26 4:45–5:05 PM
Back to top